

## Special Issue

# CAR T Cells in Solid Tumors: Current State and Future Direction

### Message from the Guest Editors

CAR T-cell therapy has achieved unprecedented clinical responses against certain advanced and treatment refractory B lymphocyte malignancies, leading to first regulatory approval of CD19-directed CAR-T cells in 2018. Non-hematological solid tumors, however, have proven less responsive to CAR T-cells, and cross-reactivity against healthy tissues is an important safety issue. Limited homing, along with barriers imposed by the stroma, can restrict the number of CAR-T cells reaching the solid tumor bed. Moreover, a range of obstacles, including limited oxygen and nutrients, as well as the presence of suppressive immune infiltrate, can lead to CAR-T cell anergy or exhaustion. This Special Issue aims to provide the current status of CAR T cells in the treatment of solid tumors, as well cutting-edge cell culture, CAR-design, gene-engineering, and combinatorial approaches for overcoming challenges in the field.

---

### Guest Editors

Prof. Dr. Arjan Griffioen

Dr. Melita Irving

Prof. George Coukos

---

### Deadline for manuscript submissions

closed (1 October 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/40949](https://mdpi.com/si/40949)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)